C4 Therapeutics, Inc.
$3.39
-$0.02 (-0.73%)
$3.38Day Range$3.48
Key Statistics
Market Cap
$417.06M
Shares Outstanding
123.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 2, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$3.43
Day High
$3.48
Day Low
$3.38
Volume
1.63M
VWAP
$3.41
Prev Close
$3.42
Transactions
--
Acc. Volume
--
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836104 employees490 ARSENAL WAY, WATERTOWN, MA, 02472(617) 231-0700IPO Oct 2, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001662579
- Composite FIGI
- BBG00BV2Y9B7
- Share Class FIGI
- BBG00BV2Y9C6
- Ticker Root
- CCCC
- SIC Code
- 2836
About C4 Therapeutics, Inc. (CCCC) Stock
C4 Therapeutics, Inc. (CCCC) closed the 2026-09-18 session at $3.39, down 0.73% versus the previous close (-0.02). The stock opened at $3.43 and traded between $3.38 and $3.48 during that session. Session trading volume was 1.6M shares. The volume-weighted average price (VWAP) is $3.41.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
C4 Therapeutics, Inc. has a market capitalization of $417.1 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CCCC is listed on the XNAS exchange. The company employs approximately 104 people. C4 Therapeutics, Inc. is headquartered in WATERTOWN, MA. The recorded listing date is 2020-10-02.
On this page you can find market CCCC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.